活体与尸体供肾对胰肾序贯移植胰腺结局的影响
单中心回顾性分析比较PAldK(n=18)、PAddK(n=28)与SPK(n=139)的胰腺结局。所有组胰腺存活率相似,但仅纳入移植后90天有功能移植物的患者时PAldK胰腺存活较差(P=0.004)。PAldK急性排斥反应显著增加(67%),多因素Cox回归显示PAldK是急性排斥的唯一预测因子(HR 6.82,95%CI 1.51-30.70,P<0.05)。
要点
- PAldK患者胰腺急性排斥风险显著高于PAddK和SPK,HR达6.82。
- 活体供肾后序贯胰腺移植的胰腺存活率在90天有功能移植物中较差。
- 供受者HLA错配及肾-胰供者重复HLA错配与胰腺排斥或存活无关。
核心结论
- 与PAddK和SPK相比,PAldK患者的胰腺移植物结局更差,表现为急性排斥增加和90天有功能移植物存活率降低。
研究设计与样本
- 单中心回顾性分析自2007年所有胰腺移植,比较PAldK(n=18)、PAddK(n=28),以SPK(n=139)为参考。
主要发现
- 胰腺存活率在所有组间相似,但仅纳入移植后90天有功能移植物的患者时PAldK存活较差(P=0.004)。
- PAldK胰腺急性排斥率为67%(1.8±1.4次/移植物),显著高于PAddK(25%)和SPK(32%)(P<0.05)。
- 多因素Cox回归中PAldK是急性排斥的唯一预测因子(HR 6.82,95%CI 1.51-30.70,P<0.05)。
- 供受者HLA错配与移植物排斥无关联;肾-胰供者重复HLA错配(0 vs 1-6)与胰腺排斥或存活无关(P>0.05)。
临床怎么用
- 对于活体供肾后序贯胰腺移植的患者,应警惕较高的急性排斥风险,加强免疫抑制监测。
局限性
- 单中心回顾性研究,样本量较小(PAldK仅18例),结论需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pancreas outcomes in pancreas after kidney transplantation (PAK) patients have been reported as being inferior to those of patients who receive simultaneous pancreas and kidney transplantation (SPK). The influence of the kidney donor (i.e. living versus deceased) has never been previously addressed. METHODS: We retrospectively analysed all pancreas transplants performed in a single centre since 2007 and compared the outcomes between those patients who had previously received a living-donor kidney transplant (pancreas transplantation after living-donor kidney transplantation, PAldK; n = 18) or a deceased-donor kidney transplant (pancreas transplantation after deceased-donor kidney transplantation, PAddK; n = 28), using SPK (n = 139) recipients as a reference. RESULTS: Pancreas survival was similar between all groups, but inferior for PAldK when including only those with a functioning graft at day 90 post-transplantation (P = 0.004). Pancreas acute rejection was significantly increased in PAldK (67%; 1.8 ± 1.4 episodes/graft) when compared with PAddK (25%) and SPK (32%) (P < 0.05) patients. In a multivariate Cox regression model including known risk factors for pancreas rejection, PAldK was the only predictor of acute rejection (hazard ratio 6.82, 95% confidence interval 1.51-30.70, P < 0.05). No association was found between donor-recipient HLA mismatches and graft rejection. Repeated HLA mismatches between kidney and pancreas donors (0 versus 1-6) did not correlate with pancreas graft rejection or survival in either PAK transplantation group (P > 0.05). CONCLUSION: Pancreas graft outcomes are worse for PAldK when compared with PAddK and SPK patients.
引用
- Ventura-Aguiar P, Ferrer J, Revuelta I, et al. Pancreas outcomes between living and deceased kidney donor in pancreas after kidney transplantation patients. Nephrol Dial Transplant. 2018. PMID: 29893956. doi:10.1093/ndt/gfy133
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。